One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.

As the saying goes, “If you don’t laugh, you’ll cry.” Biogen and ad agency 21Grams took that mantra to heart with their Gold ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

NEW YORK – The UK's National Institute for Health and Care Excellence on Thursday issued two final guidances, in which it recommended against making Eisai and Biogen's Leqembi (lecanemab) and Eli ...

Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a ...

And more pharma news updates from Pharmalittle.

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in systemic lupus erythematosus, according to data presented at the EULAR 2025 ...

Many established medical therapies to treat myasthenia gravis remain in use, and newer options are available for patients who ...

The dry AMD treatment market is experiencing unprecedented growth, driven by increasing disease awareness, rising prevalence of age-related eye cond ...

The researchers used their robot for various applications, including to bring droplets together, in some cases starting a ...